Catalyst Pharmaceuticals Inc (CPRX) to Post Q3 2018 Earnings of ($0.08) Per Share, Oppenheimer Forecasts

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Oppenheimer raised their Q3 2018 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued on Thursday, August 9th. Oppenheimer analyst L. Gershell now expects that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). Oppenheimer currently has a “Buy” rating and a $6.00 target price on the stock. Oppenheimer also issued estimates for Catalyst Pharmaceuticals’ Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.30) EPS, Q1 2019 earnings at ($0.09) EPS, Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at $0.01 EPS, Q4 2019 earnings at $0.05 EPS, FY2019 earnings at ($0.07) EPS and FY2021 earnings at $0.76 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02.

Several other equities analysts also recently commented on the stock. ValuEngine raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 14th. BidaskClub raised shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 9th. Finally, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $5.71.

Shares of NASDAQ:CPRX opened at $2.94 on Monday. The stock has a market cap of $304.72 million, a PE ratio of -14.00 and a beta of 1.20. Catalyst Pharmaceuticals has a 12 month low of $2.18 and a 12 month high of $4.51.

A number of hedge funds have recently added to or reduced their stakes in CPRX. Lido Advisors LLC bought a new position in Catalyst Pharmaceuticals in the first quarter worth about $142,000. MetLife Investment Advisors LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth about $144,000. New York State Common Retirement Fund raised its stake in Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 24,200 shares in the last quarter. GSA Capital Partners LLP bought a new position in Catalyst Pharmaceuticals in the first quarter worth about $230,000. Finally, Rhumbline Advisers raised its stake in Catalyst Pharmaceuticals by 34.7% in the second quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 23,383 shares in the last quarter. 51.31% of the stock is owned by institutional investors.

In other news, Director Donald A. Denkhaus acquired 20,000 shares of the stock in a transaction dated Wednesday, May 30th. The stock was purchased at an average cost of $3.75 per share, with a total value of $75,000.00. Following the completion of the purchase, the director now owns 120,000 shares in the company, valued at approximately $450,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have bought 29,000 shares of company stock valued at $106,940. Insiders own 9.30% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Read More: How are Outstanding Shares Different from Authorized Shares?

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply